Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines for hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Its products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and RabEnd, a animal rabies vaccine. The company has also completed a phase I clinical trial of a SARS vaccine. In addition, it develops the EV71 vaccine, which has completed clinical trials. Further, the company develops a pipeline of vaccine candidates in the clinical and pre-clinical development phases, including human vaccines for pneumococcal, rotavirus, rabies, varicella, and rubella that are in pre-clinical stage. It has a collaboration agreement with Tianjing CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.